Claims for Patent: 6,080,589

Summary for Patent: 6,080,589

Title:	Neisseria meningitidis capsular polysacchride conjugates
Abstract:	Capsular polysaccharides containing multiple sialic acid residues, particularly the Group B polysaccharide of Neisseria meningitidis, are modified by chemical reaction to randomly introduce pendant reactive residues of heterobifunctional linker molecules to the polysaccharide backbone. The capsular polysaccharide is deacetylated and the heterobifunctional linker molecule is reacted with the deacetylated material and any residual amino groups are blocked by reaction with alkyl acid anhydride. The introduction of the linker molecules to the polysaccharide chain between the termini enables the polysaccharide to be linked to a carrier molecule, such as a protein, to enhance the immunogenicity of the polysaccharide. The conjugate molecule may be formulated as an immunogenic composition for raising antibodies in a host to the polysaccharide.
Inventor(s):	Kandil; Ali (Willowdale, CA), Chong; Pele (Richmond Hill, CA), Klein; Michel H. (Willowdale, CA)
Assignee:	Connaught Laboratories Limited (North York, CA)
Application Number:	09/061,189
Patent Claims:	1. A conjugate molecule, comprising: a modified capsular polysaccharide containing multiple sialic acid derivations which contains at least one moiety of formula (I): ##STR7## wherein A is a residue of a heterobifunctional linker molecule, and a carrier molecule linked to said modified polysaccharide through said bifunctional molecule. 2. The conjugate molecule of claim 1 which contains up to about 5 of the moieties of formula (I). 3. The conjugate molecule of claim 1 which also contains at least one moiety of the formula (II): ##STR8## wherein R.sub.1 is a lower alkonyl group. 4. The conjugate molecule of claim 1 which consists of a plurality of moieties of formula (II) and at least one moiety of formula (I). 5. The conjugate molecule of claim 4 which contains up to about 5 moieties of formula (I). 6. The conjugate molecule of claim 5 which contains from about 10 to about 40 total moieties of formula (I) and formula (II). 7. The conjugate molecule of claim 5 wherein said heterobifunctional linker molecule is selected from the group consisting of sulfosuccinimidyl(4-iodoacetyl)aminobenzoate, m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester, N-succinimidyl 3-(2-pyridyldithio)propionate, and sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate. 8. The conjugate molecule of claim 7 wherein said R.sub.1 group is a propionyl group. 9. The conjugate molecule of claim 1 wherein said carrier molecule is a protein, a peptide or a solid matrix. 10. The conjugate molecule of claim 8 wherein said protein is selected from the group consisting of tetanus toxoid, diphtheria toxoid, cholera toxin and an outer membrane protein of Haemophilus, including P1, P2, P6, D15, Hin 47, transferrin receptor, lactoferrin receptor, and hemin binding proteins. 11. The conjugate molecule of claim 1 wherein said capsular polysaccharide is a polysaccharide of Neisseria. 12. The conjugate of claim 11 wherein said Neisseria capsular polysaccharide is a Group B polysaccharide of Neisseria meningitidis. 13. A method of forming a modified capsular polysaccharide containing multiple sialic acid derivatives, which comprises: deacetylating at least a substantial proportion of the acetyl groups from the capsular polysaccharide containing multiple sialic acid groups to provide a deacetylated molecule, and reacting said deacetylated molecule with (i) a heterobifunctional linker molecule having one functional group capable of reacting with free amino groups in the deacetylated molecule in an amount sufficient to reactively couple at least one of said linker molecules to the deacetylated molecule at at least one free amino group contained therein, and (ii) an alkyl acid anhydride capable of reacting with free amino groups in the deacetylated molecule, in an amount sufficient to react said alkyl acid anhydride with any free amino groups in said deacetylated molecule not reacted with said linker molecule, thereby to produce a modified capsular polysaccharide containing at least one moiety of the formula I: ##STR9## wherein A is a heterobifunctional linker molecule and the remaining moieties of formula II: ##STR10## wherein R.sub.1 is a lower alkanoyl group. 14. The method of claim 13 wherein substantially all the acetyl groups are removed. 15. The method of claim 13 wherein said heterobifunctional linker is employed in an amount sufficient to provide from about 1 to about 5 of the moieties of formula (I). 16. The method of claim 15 wherein said modified polysaccharide contains a total of from about 10 to about 40 moieties of formula (I) and formula (II). 17. The method of claim 16 wherein said heterobifunctional linker is selected from the group consisting of sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo SIAB), m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (sulfo-MBS), N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), and sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate. 18. The method of claim 17 wherein said alkyl acid anhydride is propionic anhydride or acetic anhydride. 19. The method of claim 18 including further comprising reacting the free functional group on said heterobifunctional linker molecule on said modified polysaccharide with a carrier molecule to couple the carrier molecule to the modified polysaccharide through the heterobifunctional linker molecule. 20. The method of claim 19 wherein said carrier molecule is a protein, a peptide or a solid matrix. 21. The method of claim 13 wherein said capsular polysaccharide is a polysaccharide of Neisseria. 22. The method of claim 21 wherein said Neisseria capsular polysaccharide is a Group B polysaccharide of Neisseria meningitidis. 23. An immunogenic composition, comprising a conjugate molecule as claimed in claim 1 and a carrier therefor. 24. A method of generating an immune response in a host, comprising administering thereto an immuno-effective amount of the immunogenic composition of claim 23. 25. A method of determining the presence of antibodies specifically reactive with a capsular polysaccharide containing multiple sialic acid groups in a sample, comprising the steps of: (a) contacting the sample with the conjugate molecule of claim 1 to produce complexes comprising the conjugate molecule and any said antibodies present in the sample specifically reactive therewith; and (b) determining production of the complexes. 26. The method of claim 25 wherein said capsular polysaccharide is a Group B polysaccharide of Neisseria meningitidis. 27. A method of determining the presence of a capsular polysaccharide containing multiple sialic acid groups in a sample, comprising the steps of: (a) immunizing a subject with the immunogenic composition of claim 23 to produce antibodies specific for said polysaccharide; (b) isolating the polysaccharide specific antibodies; (c) contacting the sample with the isolated antibodies to produce complexes comprising any said capsular polysaccharide present in the sample and said isolated polysaccharide specific antibodies; and (d) determining production of the complexes. 28. The method of claim 27 wherein said capsular polysaccharide is a Group B polysaccharide of Neisseria meningitidis. 29. A diagnostic kit for determining the presence of antibodies in a sample specifically reactive with Group B polysaccharide of a Neisseria meningitidis strain, comprising: (a) the conjugate molecule of claim 1; (b) means for contacting the conjugate molecule with the sample to produce complexes comprising the conjugate molecule and any said antibodies present in the sample; and (c) means for determining production of the complexes. 30. A diagnostic kit for determining the presence of a Group B polysaccharide of a Neisseria meningitidis strain in a sample, comprising: (a) a Group B polysaccharide specific antibody to the immunogenic composition of claim 23; (b) means for contacting the antibody with the sample to produce a complex comprising said Group B polysaccharide and the antibody; and (c) means for determining the production of the complex. 31. A method of producing monoclonal antibodies specific for a capsular polysaccharide containing multiple sialic acid group comprising: (a) administering the conjugate molecule of claim 1 to at least one mouse to produce at least one immunized mouse; (b) removing B-lymphocytes from the at least one immunized mouse; (c) fusing the B-lymphocytes from the at least one immunized mouse with myeloma cells, thereby producing hybridomas; (c) cloning the hybridomas; (d) selecting clones which produce anti-polysaccharide antibodies; (e) culturing the anti-polysaccharide antibody-producing clones; and then (f) isolating anti-polysaccharide antibodies from the cultures.

Details for Patent 6,080,589

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246	07/20/1983		2015-06-07